Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)
China · Delayed Price · Currency is CNY 11.55
-0.37 (-3.10%)
Sep 10, 2026, 1:15 PM CST
SHA:603439 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,825 | 4,735 | 5,205 | 7,738 | 5,637 | 6,483 | |
Market Cap Growth | -9.13% | -9.02% | -32.74% | 37.27% | -13.05% | -21.44% |
Enterprise Value | 5,216 | 5,285 | 5,445 | 7,421 | 5,342 | 6,161 |
Last Close Price | 11.92 | 11.65 | 12.57 | 17.99 | 13.00 | 14.96 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12892.19 | 102.38 | 18.99 | 26.44 | 28.01 | 42.58 |
Forward PE | - | 10.60 | 13.81 | 26.53 | 25.89 | - |
PS Ratio | 3.09 | 2.78 | 2.43 | 4.73 | 4.69 | 6.91 |
PB Ratio | 3.14 | 3.13 | 3.26 | 4.53 | 4.55 | 6.28 |
P/TBV Ratio | 5.69 | 5.78 | 6.88 | 11.37 | 5.81 | 6.41 |
P/FCF Ratio | 21.02 | 34.13 | 84.12 | 46.07 | 32.51 | 50.27 |
P/OCF Ratio | 18.66 | 28.77 | 48.61 | 27.97 | 19.22 | 41.82 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.34 | 3.10 | 2.54 | 4.54 | 4.45 | 6.56 |
EV/EBITDA Ratio | 23.80 | 20.42 | 13.51 | 24.44 | 24.24 | 37.78 |
EV/EBIT Ratio | 35.11 | 28.41 | 16.58 | 27.77 | 26.11 | 40.56 |
EV/FCF Ratio | 22.72 | 38.09 | 88.00 | 44.18 | 30.81 | 47.77 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.42 | 0.50 | 0.38 | 0.33 | 0.17 | 0.19 |
Debt / EBITDA Ratio | 2.90 | 2.92 | 1.50 | 1.83 | 0.93 | 1.23 |
Debt / FCF Ratio | 2.77 | 5.47 | 9.81 | 3.30 | 1.19 | 1.55 |
Net Debt / Equity Ratio | 0.21 | 0.23 | 0.07 | -0.04 | -0.34 | -0.43 |
Net Debt / EBITDA Ratio | 1.49 | 1.35 | 0.27 | -0.22 | -1.93 | -2.71 |
Net Debt / FCF Ratio | 1.41 | 2.51 | 1.74 | -0.40 | -2.45 | -3.43 |
Asset Turnover | 0.57 | 0.56 | 0.70 | 0.69 | 0.75 | 0.71 |
Inventory Turnover | 1.53 | 1.91 | 2.63 | 3.20 | 3.64 | 4.07 |
Quick Ratio | 1.35 | 1.22 | 1.16 | 1.56 | 1.94 | 2.79 |
Current Ratio | 1.71 | 1.48 | 1.46 | 1.78 | 2.14 | 3.05 |
Return on Equity (ROE) | 0.04% | 3.10% | 16.94% | 20.01% | 16.91% | 14.76% |
Return on Assets (ROA) | 3.38% | 3.85% | 6.71% | 7.05% | 7.94% | 7.13% |
Return on Invested Capital (ROIC) | 0.25% | 7.42% | 16.91% | 19.22% | 25.16% | 21.45% |
Return on Capital Employed (ROCE) | 8.10% | 10.30% | 16.80% | 12.80% | 16.10% | 14.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.01% | 0.98% | 5.27% | 3.78% | 3.57% | 2.35% |
FCF Yield | 4.76% | 2.93% | 1.19% | 2.17% | 3.08% | 1.99% |
Dividend Yield | 0.49% | 0.52% | 2.70% | 1.11% | 0.77% | - |
Payout Ratio | 12375.40% | 349.04% | 37.97% | 17.40% | 4.43% | 72.37% |
Buyback Yield / Dilution | -1.10% | -2.81% | 0.79% | -0.36% | 0.19% | -5.14% |
Total Shareholder Return | -0.61% | -2.30% | 3.50% | 0.75% | 0.96% | -5.14% |